Saatja: Elen Ohov </o=JM/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d1f60c90fe9d4133827e2e90805100fd-Elen Ohov>
Saaja: 'PANAGIOTAKI, Katerina', '
[email protected]', KÖHLER, Kristina, Tairi Täht
Teema: RE: Reminder: Nomination of focal point for WHO Europe Access to Novel Medicines Platform
Dear Ms Delaney,
Estonian Ministry of Social Affairs would like to nominate as focal point to the WHO Europe Access to Novel Medicines Platform:
Ms Tairi Täht
Adviser, Medicine Department
Ministry of Social Affairs
[email protected] <mailto:
[email protected]>
+372 6269 183
Best regards
Elen Ohov
Adviser | European Union Affairs and International Co-operation Department
+372 626 9241|
[email protected]
Ministry of Social Affairs
Suur-Ameerika 1 | 10122 Tallinn
626 9301 | http://www.sm.ee <http://www.sm.ee/et>
From: PANAGIOTAKI, Katerina <
[email protected]>
Sent: Thursday, December 8, 2022 2:30 PM
To: Peep Peterson <
[email protected]>; Triin Uusberg <
[email protected]>; Elen Ohov <
[email protected]>
Cc: Elen Ohov <
[email protected]>; Triin Uusberg <
[email protected]>; SM Info <
[email protected]>; Ms K. Saarsalu-Layachi (
[email protected]) <
[email protected]>;
[email protected]; Kaisa.Mitt-Alvarez <
[email protected]>;
[email protected];
[email protected]; KÖHLER, Kristina <
[email protected]>; DELANEY, Louise <
[email protected]>; EURONMP <IMCEAEX-_o=ExchangeLabs_ou=Exchange+20Administrative+20Group+20+28FYDIBOHF23SPDLT+29_cn=Recipients_cn=e295812b1b87461fbe02d903c190de09-2947628b-b1@eurprd01.prod.exchangelabs.com>
Subject: Reminder: Nomination of focal point for WHO Europe Access to Novel Medicines Platform
The Novel Medicines Platform (NMP) Secretariat wishes to send you a gentle reminder that we are looking forward to receiving your nomination of focal point for the upcoming consultation with Member States. If you have any questions about the consultation process or the platform, please feel free to contact us.
Thank you for your consideration.
The NMP Secretariat
From: PANAGIOTAKI, Katerina
Sent: Friday, November 25, 2022 10:24 AM
To:
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]>
Cc:
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ;
[email protected] <mailto:
[email protected]> ; KÖHLER, Kristina <
[email protected] <mailto:
[email protected]> >; DELANEY, Louise <
[email protected] <mailto:
[email protected]> >; EURONMP
Subject: Nomination of focal point for WHO Europe Access to Novel Medicines Platform
Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachements may be included.
Veuillez-vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalbüro für Europa.
См. прикрепленное письмо от Европейского регионального бюро Всемирной организации здравоохранения (один или несколько прикрепленных файлов).
Sent on behalf of
Office of the Regional Director
World Health Organization Regional Office for Europe
UN CITY, Marmorvej 51, DK-2100 Copenhagen, Denmark
Phone +45 4533 7095 / 6788
Web: www.euro.who.int <http://www.euro.who.int/>
Follow WHO on Facebook <https://www.facebook.com/WHO> ; Twitter <https://twitter.com/WHO> ; YouTube <https://www.youtube.com/user/who?sub_confirmation=1> ; Instagram <https://www.instagram.com/who/>